This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): interferon beta-1a
Description: Avonex has been available since 1996, and is currently indicated for (1) the treatment of patients with relapsing forms of multiple sclerosis (MS) to both slow the advancement of physical disability and decrease the frequency of clinical exacerbations, and (2) treatment of patients with a first MS attack when brain MRI scan abnormalities characteristic of MS are demonstrated.
Domp and Biogen
A joint venture collaboration between Biogen and Domp began in 1997 as Biogen Domp in Italy and Switzerland. Initially, the joint ventures were responsible for the commercialization of Avonex. They were then expanded to include commercial, distribution and service rights for Tysabri upon the therapy's approval in each respective market.
In September 2011, Biogen Idec announced the company will acquire 100% of Domp shares in its joint ventures in both Italy and Switzerland.
Abbott and Biogen
In April 1998, Abbott and Biogen signed an agreement providing Abbott marketing rights for Avonex in Latin America.
Genzyme and Biogen
In September 1998, Genzyme announced an agreement with Biogen under which Genzyme will commercialize and exclusively distribute Avonex in Japan, following regulatory approval. Under the agreement, Genzyme will be responsible for managing a clinical development program for Avonex and will work with...See full deal structure in Biomedtracker
Partners: Abbott Laboratories UCB SA
Additional information available to subscribers only: